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Microbial fermentation: New tools to 
speed-up vaccine antigen development 
and increase process knowledge
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Albufeira, Portugal
2SANOFI PASTEUR : 
The vaccines division of SANOFI group
● World leader in vaccines
● 20 diseases
● More than 1 billion doses/year
● More than 500 million people 
vaccinated/year
● 13 vaccines in development(1)
● Nearly 13,000 employees(2)
● 12 production/R&D sites in the world
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● France (Marcy l’Etoile and Val de Reuil)
● US (Swiftwater, Cambridge, Canton, 
Orlando and Rockville)
● Canada (Toronto)
● Argentina (Pilar)
● China (Shenzhen)
● India (Hyderabad)
● Thailand (Chachoengsao)
And 3 new facilities under construction: Mexico 
(Ocoyoacac), France (Neuville) and China 
(Shenzhen)
1. As of July 28, 2011, from phase I  to “submitted”
2. FTEs as of December 2010 – Vaccines activities Sites Sanofi Pasteur
Viral diseases
Yellow fever
Mumps
Poliomyelitis 
Measles
Bacterial diseases
Pertussis
Diphtheria
Haemophilus influenzae type b Infections 
Meningococcal meningitis
● The site manufactures vaccines against 11 of the 20 diseases that Sanofi Pasteur’s
vaccines protect against throughout the world 
MARCY L’ETOILE, 
OUR VACCINES
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Rubella 
Influenza
Hepatitis A
Hepatitis B
Rabies
Japanese Encephalitis 
Chickenpox
Pneumococcal infections
Tetanus
Tuberculosis
Typhoid Fever
Cholera 
Marcy l’Etoile also purifies 
immunoglobulins
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Microbial fermentation
Innovative tools for high density aerobic and pathogenic strains
Standard stainless 
steel bioreactors
20-2000L
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Small scale production Process Development Scale-up
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In-Process
Analytic
Microbial fermentation
Different sequential process screening/development platforms
● Tools architecture organized in each platform to speed-up strain selection, 
process development and optimization of industrial processes
SCREENING PLATFORM
for clone selection
PROCESS DEVELOPMENT INDUSTRIAL PROCESS 
OPTIMIZATION
Aerobic & Anaerobic strains
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Supply for preclinical study
Implementation in
Industrial facility
Phase III-Commercial
Process for Phase I/II
Recombinant         Pathogens
Strains 
Selection 
Preclinical 
material 
supply
Screening platform
µscale and disposable bioreactors for fast material supply
µscale bioreactors for clone 
selection
E. coli
Transformants 
1/8
| 6
Autoinducible media
Overnight culture
Criteria of clone selection:
 Final OD
 Antigen production
Seed lot production
Efficient disposable system for 
microbial production
Production at 1L or 10L scale
Expected
protein
quality & 
quantity
2 weeks
Preliminary
Strains 
Selection 
Preclinical 
material 
supply
Culture 
condition
selection
Screening platform
Set-up of predictive µscale tools for difficult to express protein
-Shake flask in optimum 
conditions*
-µscale bioreactors  for 
microbial system*
Clones pre-
selection (3-15)                
Commercial or in 
house customized 
media:
-Composition to favor 
Strain selection based 
2/8
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 Criteria of clone 
selection:
Final OD
Antigen production
Soluble protein
X
14 preselected 
media
X
Culture conditions 
(T, pH, [IPTG] ) Set of data on strain 
behaviour
soluble protein 
production
-Defined or complexe 
media
-Different final 
biomass
-Autoinduction
-Fed batch
on its potential in 
different conditions
*Tools optimized to be representative of 20-200L scale bioreactor performances -
Based on kLa measurement in our culture conditions (media, temperature)
~8 weeks  
Screening platform
Case study: screening of different hosts/media in µ24 bioreactors
Culture 
condition
selection
● Difficult to solubilize protein for vaccine antigen subunit
● Evaluation of different culture conditions, under induction, for pre-selected functional clones: 
E. coli BL21, C41 and Artic
3/8
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● Differential behaviour among strains,  and culture conditions
0
5
10
15
20
25
BL21 C41 Arctic 
O
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medium 7
medium 8
medium 9
medium 10
medium 11
medium 12
medium 13
medium 14
● Evaluation of production in the soluble 
and insoluble fractions for each 
condition
● Main results
● Soluble fraction for the protein P1 
expressed in  E. coli Arctic host in a 
specific medium
● No soluble fraction with E. coli BL21 
Screening platform
Case study: screening of different hosts/media
BL21 P1 P1 P1
Culture 
condition
selection
4/8
| 9
whatever the culture conditions
● Next step: optimize  best clone culture 
conditions to increase the protein 
production in the soluble fraction
Screening platform
Case study: Cell tainer system® evaluation
Preclinical 
material 
supply
● Initial process in stainless steel fermentor (30L scale)
● E.coli strain, protein production induced with IPTG
● Regulations:
• pH: 7.00, 37°C, DO: 30% (cascade: stirrer , air flow then oxygen enrichment)
● Evaluated system for fast preclinical production turn around: Cell tainer system
● Flexibility (1 to 15L, batch or fed batch mode, optional on line glucose measurement 
(TRACE system)
5/8
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● Atypical agitation system allowing to reach high Kla values
● Preliminary run performed with working volume at 11 liters :
● Foam in out air filter, Oxygen limitation
● Optimal settings identified via kLa measurement :
● Working volume (7L), stirrer (45 rpm)
● Addition of anti-foam before inoculation
● Angle of agitation fixed at the maximum Max kLa value: 300h-1
Batch mode process performance
● Growth kinetics with optimum 
settings  
● similar growth and biomass between 
stainless steel reactor and cell tainer 
system
Preclinical 
material 
supply
6/8
Growth profiles
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Induction
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Post induction time (hour)
Protein production
BAT 2082 Cell Tainer
BAT 2072 Cell Tainer
FDV 01536
● Protein production analysis by SDS – PAGE / Scan
● Comparable protein expression between Cell Tainer 
and  stainless steel reference
0
0 1 2 3 4 5 6
Time of culture (hour)
● Process parameters and metabolites follow-up:
● Kinetic of glucose consumption identical to our standard process  
● No oxygen limitation but set point not maintained during the culture
● High level of acetate production at the end of the culture
Preclinical 
material 
supply
BAT 2072 & 2082 comparative : dissolved oxygen and mixing 
70
80
90
100
35
40
45
50
Mixing  RPM
% O2 BAT 2072
% O2 BAT 2082
Agitation BAT 2072
Batch mode process performance 7/8
Acetate profile (Daytona analyser)
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BAT 2072 Cell Tainer
BAT 2082 Cell Tainer
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● Fed batch process:
● Preliminary work shows than we can maintain DO above 20%
● Acetate level is low (below 2.5 g/L)
0
10
20
30
40
50
60
0 1 2 3 4 5 6 7
Fermentation time (hours)
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● First efficient E.coli batch process in a single use bioreactor
● Similar biomass (around 20g/L cdw) and protein production versus standard  fermentor
● Batch and fed batch processes capabilities
● Good reproducibility
● Advantages thanks to the high turn-around  for process development and small 
scale batches
Advantages / Perspectives
Preclinical 
material 
supply
8/8
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● However, system scalability limited for purposes beyond preclinical supplies, seed 
train, phase I GMP production
Microbial fermentation
Different sequential process screening/development platforms
● Tools architecture organized in each platform to speed-up strain selection, 
process development and optimization of industrial processes
SCREENING PLATFORM
for clone selection
PROCESS DEVELOPMENT INDUSTRIAL PROCESS 
OPTIMIZATION
Aerobic & Anaerobic strains
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Supply for preclinical study
Implementation in
Industrial facility
Phase III-Commercial
Process for Phase I/II
Recombinant         Pathogens
Industrial process optimization
Case study: µscale to industrial scale
● Aerobic pathogenic strain – Industrial process
● Aim of the study:
● To model the impact of 3 process parameters (pH, DO, T) on 
biomass and antigen production and impurity level
● To identify optimal process productivity conditions
Reference 
INDUSTRIAL PROCESS 
OPTIMIZATION 1/6
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Implementation of  
micro scale-down 
and DOE 
combination for 
process modelization 
and improvement of 
culture parameters 
for an industrial 
process
Industrial 
Scale down model 
tested
flas k
Micro -
fermentor
Fermentor
1L
Fermentor
30L
Fermentor
1000L
Working volume 150 ml 3 ml 0.5L 30L 1000L
C apacity of fermentors
available in the lab
N o limit 24 4 2 /
Biomass 
(OD
600nm
7 9 9 - 1 0 9 - 1 0 8 - 9 8 - 9
Results
Product 
yield (g/L)
0.4 0.75 0.8 0.71 0.62
● Effect of  pH on  biomass (T at  37°C , DO2 at 30%)
● Effect of  DO2 on   biomass  (no pH regulation and T at 37°C)
Experimental domain definition :
identification of limit values for each parameter investigated
domain fixed for pH : 
6.0 to 7.6
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INDUSTRIAL PROCESS 
OPTIMIZATION 2/6
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Domain fixed for DO2 :
5%  to 70%
0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23pH 5,5 pH 6,2 pH 7,00 pH 7,6 pH 7,8 pH 8,0pH 5,9
● Effect of  Temperature on  biomass  (no pH regulation, DO2 at 30%)
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25°C 30°C 37°C 40°C 42°C28°C
Domain fixed for T°: 
30°C to 40°C
DOE matrix selection  for the study
Response surface model
(central composite matrix)
• Use of the software Nemrodw®
INDUSTRIAL PROCESS 
OPTIMIZATION 3/6
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• Response surface model 
(central composite matrix)
• 21 cultures 
• 15 conditions for the DOE
• 3 repetitions of  central point
• 4 test points to validate the 
model
DOE interpretation and modelization
Impurity level
6.75
7.55
pH
Modelling of the impurity level in function of pH and temperature valuesModelling of the antigen production in function of pH and temperature values
antigen production
pH
7.55
6.75
Biomass production
pH
Modelling of the biomass in function of pH and temperature values
7.55
6.75
5.95
First answer studied : biomass production Second answer studied : antigen production Third answer studied : impurity production
INDUSTRIAL PROCESS 
OPTIMIZATION
4/6
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Dissolved O2 fixed at 30%
temperature30°C 35°C 40°C
5.95
Dissolved O2 fixed at 30%
temperature
5.95
30°C 35°C 40°C
temperature
Dissolved O2 fixed at 30%
30°C
30°C 35°C 40°C
Significant effects identified :
- pH (+++)
- Interaction pH / DO2 (++)
- Interaction temperature / pH (+)
- DO2 (+)
Significant effects identified :
- temperature (+++)
- pH (++)
- Interaction DO2 / pH (+)
- DO2 (+)
Significant effects identified :
- pH (+++)
- Interaction DO2 / temperature (+)
• Effect of the 3 parameters investigated on the 3 responses (single effect or interaction)
• But no condition allowing at the same time to maximize antigen production and minimize 
the impurity quantity
● Modelisation of the phenomena investigated in the experimental 
domain 
● Compromise  :
Identification  of conditions allowing at the same time the increase of 
the antigen production and the maintain/control impurity level
DOE interpretation and modelisation INDUSTRIAL PROCESS OPTIMIZATION
5/6
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Implementation of results obtained 
through the DOE
Confirmation of  results 
obtained with DOE at 
micro scale : 
increase of  antigen 
Settings Initial 
Fermentor 
Scale
Fermentor 
1L
DOE 
predictions 
with new 
settings
Fermentor 
1L
Fermentor 
100L
Fermentor 
1000L
OD  max (600nm) 11 12 12 11 11 .5
Product yield 
0.8 1.23 1.26 1.28 1.2 7
● Testing of new settings at intermediary scales (fermentors 1liter and 100 liters) 
then at industrial scale (fermentor 1000 liters)
INDUSTRIAL PROCESS 
OPTIMIZATION
6/6
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production confirmed up 
to  industrial scale
(g/L)
Impurity Level 
(UI/ml)
900 000 800 000 95 0 000 69 0 000 78 0 000
● Technological evolution in the single use domain
● For microbial fermentation new single-use and µscale bioreactors have been recently 
developed than can deal with the high oxygen demand
● Benefits of the single use and µscale bioreactors implementation
● Conduce fast expression system screening to select best host, clone, media, vector for 
antigen production at the expected quality and quantity 
● Generate predictible results at industrial scale thanks to parameters regulation
● Increase process knowledge and robustness through DoE with limited workload
● Reduced time of process development trough downscale, multiple parallel bioreactors
Conclusion
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● Ressource allocated to core expertise instead of non value tasks (cleaning, bioreactor 
decontamination)
● Lead significant increase  of the antigen production for two industrial processes
● Next steps
● Implementation of highthrough-put sample treatment, 
● Automation of the different steps (culture, sampling, sample treatment, analytics), 
● Data management
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Thank you!
Questions ? 
Jean Marc GUILLAUME –Head of 
Bioprocess R&D  USP platform
